Trial reportMedical science monitor : international medical journal of experimental and clinical research2014
Effects of sertraline on executive function and quality of life in patients with advanced cancer.
Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Effect of Refined Nursing on Wound Complications After Thoracoscopic Surgery for Lung Cancer.The clinical respiratory journal · 2025Trial
- Effect of comprehensive nursing intervention on the formation of pressure sore in patients undergoing orthopaedic surgery in prone position.International wound journal · 2024Trial
- Associations Between Neurobehavioral Symptoms During Breast Cancer Chemotherapy and Patient-Reported Cognitive Impairment 3 or More Years After Chemotherapy.Psycho-oncology · 2026Article
- Effects of preoperative psychological stress on selected parameters in older patients undergoing total hip arthroplasty.World journal of psychiatry · 2025Article
- Longitudinal Analysis of Patient-Reported Cognitive Function in Multiple Myeloma.Clinical lymphoma, myeloma & leukemia · 2022Article
- Article
- A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer.Brain, behavior, & immunity - health · 2022Review
- Complex Effects of Sertraline and Citalopram on In Vitro Murine Breast Cancer Proliferation and on In Vivo Progression and Anxiety Level.International journal of molecular sciences · 2022Article
- Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Review
- Long-Term Cognitive Dysfunction in Cancer Survivors.Frontiers in molecular biosciences · 2021Review
- Acupuncture for the treatment of marrow suppression after chemotherapy: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Repurposing antidepressant sertraline as a pharmacological drug to target prostate cancer stem cells: dual activation of apoptosis and autophagy signaling by deregulating redox balance.American journal of cancer research · 2020Article
- Pharmacological Management of Anxiety Disorders in the Elderly.Current treatment options in psychiatry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to investigate effects of the antidepressant sertraline on executive function and quality of life in patients with advanced cancer. MATERIAL/
methodsWe assigned 122 patients with stage III or IV cancer to the depressed group (DG, n=86) or the non-depressed group (NG, n=36). All subjects were given supportive treatment and patients in the DG received additional antidepressant treatment.
resultsThere were significant differences in total scores of the Hamilton anxiety scale (HAMA) and the Hamilton depression scale (HAMD), performance in the Wisconsin card sorting test, and SF-36 domains. After antidepressant treatment, the level of depression and anxiety decreased significantly in the DG, but was still significantly higher than in the NG. Low executive function was enhanced in the DG, but a worsening executive function was found in total errors in the NG (-2.3±3.8) (P<0.05). The dimensions of SF-36 in physical functioning (PF), role limitations-physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations-emotional (RE), and mental health (MH) were decreased significantly at baseline in the DG compared to the NG (P<0.01). After 12-week Sertraline treatment, improvement in the DG in factors VT, SF, RE, and MH were more powerful than in the NG (P<0.05). HAMA, HAMD, and VAS scores and tumor stage were significantly correlated to any one dimension of quality of life.
conclusionsDepression is an important cause of decreased quality of life and executive function in patients with advanced cancer. The antidepressant sertraline can improve the executive function and quality of life, which may be helpful in the clinical practice of cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.